-transparent.png){kind=logo}
Eosinophilic gastritis and eosinophilic enteritis (EoG/EoN) are associated with a substantial clinical burden. However, limited information is available regarding the economic burden of EoG/EoN. This study was conducted to compare healthcare resource use (HRU) and costs among patients with EoG/EoN versus without EoG/EoN in the USA. Administrative claims data from the IBM MarketScan® Commercial Claims and Encounters (CCAE) and Medicare Supplemental and Coordination of Benefits Databases (2009-2019) was used to identify two cohorts of patients. Patients without EoG/EoN were matched 3:1 to patients with EoG/EoN on sex, year of birth, and healthcare plan type. Study measures included demographic characteristics, select comorbidities, all-cause HRU, and costs. Comparisons were made over a 1-year period following EoG/EoN diagnosis for patients with EoG/EoN and an eligible date for patients without EoG/EoN. A total of 2219 patients with EoG/EoN and 6657 patients without EoG/EoN were analyzed. Significantly higher proportions of patients with EoG/EoN versus without EoG/EoN had comorbid conditions. Rates of all-cause HRU were significantly higher among patients with EoG/EoN versus patients without EoG/EoN (adjusted rate ratio [95% confidence interval]: inpatient visits, 6.26 [5.26, 7.46]; outpatient visits, 1.17 [1.16, 1.19]; emergency department visits, 2.11 [1.98, 2.25]; all p < 0.001). Patients with EoG/EoN incurred significantly higher costs versus patients without EoG/EoN (adjusted mean cost difference $31,180; p < 0.001). Cost differences were largely due to outpatient (adjusted mean cost difference $14,018; p < 0.001) and inpatient (adjusted mean cost difference $11,224; p < 0.001) costs. The economic burden associated with EoG/EoN is substantial, with patients with EoG/EoN having a higher rate of HRU and incurring $31,180 more than patients without EoG/EoN on average. Most of the cost difference was attributable to outpatient and inpatient costs. Cost-saving strategies to lower the burden of illness in this patient population are needed.
Michael Woolley, and
Erin E Cook, and
Fan Mu, and
Keith A Betts, and
Emma Billmyer, and
Erica Yim, and
Jingyi Chen, and
Eric Q Wu
May 1984,
Harefuah,
Michael Woolley, and
Erin E Cook, and
Fan Mu, and
Keith A Betts, and
Emma Billmyer, and
Erica Yim, and
Jingyi Chen, and
Eric Q Wu
October 2022,
The Journal of clinical psychiatry,
Michael Woolley, and
Erin E Cook, and
Fan Mu, and
Keith A Betts, and
Emma Billmyer, and
Erica Yim, and
Jingyi Chen, and
Eric Q Wu
November 2023,
Research square,
Michael Woolley, and
Erin E Cook, and
Fan Mu, and
Keith A Betts, and
Emma Billmyer, and
Erica Yim, and
Jingyi Chen, and
Eric Q Wu
June 2018,
Vaccine,
Michael Woolley, and
Erin E Cook, and
Fan Mu, and
Keith A Betts, and
Emma Billmyer, and
Erica Yim, and
Jingyi Chen, and
Eric Q Wu
April 2022,
Open forum infectious diseases,
Michael Woolley, and
Erin E Cook, and
Fan Mu, and
Keith A Betts, and
Emma Billmyer, and
Erica Yim, and
Jingyi Chen, and
Eric Q Wu
February 2022,
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Michael Woolley, and
Erin E Cook, and
Fan Mu, and
Keith A Betts, and
Emma Billmyer, and
Erica Yim, and
Jingyi Chen, and
Eric Q Wu
March 2024,
American journal of ophthalmology,
Michael Woolley, and
Erin E Cook, and
Fan Mu, and
Keith A Betts, and
Emma Billmyer, and
Erica Yim, and
Jingyi Chen, and
Eric Q Wu
February 2023,
The American journal of gastroenterology,
Michael Woolley, and
Erin E Cook, and
Fan Mu, and
Keith A Betts, and
Emma Billmyer, and
Erica Yim, and
Jingyi Chen, and
Eric Q Wu
April 2003,
Journal of the American Academy of Dermatology,
Michael Woolley, and
Erin E Cook, and
Fan Mu, and
Keith A Betts, and
Emma Billmyer, and
Erica Yim, and
Jingyi Chen, and
Eric Q Wu
June 2015,
Journal of the American Academy of Dermatology,
